FDA Safety Note: The FDA has raised concerns regarding some unapproved compounded GLP-1 products, including dosing errors and the use of semaglutide salt forms (such as semaglutide sodium or acetate), which differ from the active ingredient used in FDA-approved medications
"We have cases which have shown melanoma developing after trying them
Gastrointestinal side effects from semaglutide (nausea, constipation) are common but temporary and differ from thyroid-related symptoms
The magnitude of weight loss varies by product: semaglutide 2.4mg (Wegovy) can achieve approximately 15% reduction in body weight, while liraglutide 3mg (Saxenda) typically produces around 8% weight loss
Hasan Maleki M, Siri M, Jafarabadi A, Rajabi M, Amirhossein Mazhari S, Noori Z, et al